In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi,...
